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Hepatitis E virus (HEV) infection can be responsible for chronic hepatitis in immunocompromised patients, and can rapidly evolve into 
fibrosis and/or hepatic cirrhosis. We present two cases of chronic hepatitis E, emphasizing the need to be aware of this entity as a growing 
etiology of hepatitis in transplant and immunocompromised patients. 
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Introduction 
Hepatitis E is caused by a single strain RNA virus, 
hepatitis E virus (HEV), which is  transmitted 
enterically and is responsible for a significant number 
of cases of acute hepatitis with endemic characteristic 
in several developing countries in Asia, the Middle 
East, Africa, and Central America (genotypes 1 and 2), 
and is generally sporadic in the United States and 
developed countries in Europe (genotypes 3 and 4) [1]. 
In immunocompetent patients, infection is usually 
self-limited, evolving to chronicity only in cases of 
immunosuppression [1]. Such cases include transplant 
patients (mainly kidney and liver), today recognized as 
a risk group, where HEV infection has emerged in 
developed countries [2]. As in other non-endemic 
countries, there are reports of autochthonous infection 
Portugal [3] as well as reports of the presence of anti-
HEV antibodies in healthy individuals [4]. 
Herein we report two cases of chronic hepatitis E 
in patients who had undergone kidney transplantation, 
were under immunosuppressive therapy, and had 
prolonged elevation of aminotransferases.  
 
Case 1 
The first case was a 55-year-old Caucasian male 
who received a kidney transplant from a deceased 
donor in April 2011 for chronic kidney disease (CKD) 
of unknown cause. He had past medical history of 
hypertension, depression and chronic sinusitis, and 
was medicated with enalapril, trazodone, and 
alprazolam. His body mass index (BMI) was 24.4 
Kg/m2. He was an active smoker and denied alcohol 
consumption and recent travel abroad. His 
immunosuppressive regimen included tacrolimus (4 
mg once daily), mycophenolate mofetil (500 mg twice 
daily), and prednisolone (5 mg once daily). Three 
months after receiving the transplant, he developed an 
asymptomatic increase in aminotransferases, with 
aspartate aminotransferase (AST) two times the upper 
limit of normal (2x ULN), alanine aminotransferase 
(ALT) 3x ULN, and gamma glutamyl transferase 
(GGT) 3x ULN. Hepatitis B virus (HBV), hepatitis C 
virus (HCV), human immunodeficiency virus (HIV) 1 
and 2, Epstein-Barr virus (EBV), herpes simplex virus 
(HSV) 1 and 2, and cytomegalovirus (CMV) 
serologies were negative. DNA HBV and RNA HCV 
were undetectable. Liver autoimmunity screening was 
negative. Abdominal ultrasound was normal. During 
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the following months, he maintained a fluctuating 
evolution of liver enzymology with AST under 1.5x 
ULN, ALT 2x ULN, and GGT 3x ULN. In December 
2011, he was admitted for acute cellular rejection of 
the kidney allograft and interstitial nephritis; DNA-
polyomavirus was detected by polymerase chain 
reaction (PCR). Due to the  high plasma viral load of 
BKV, his immunosuppressive regimen was changed; 
cyclosporine (150 mg twice daily) and prednisolone 
(20 mg once daily) were initiated. The percutaneous 
liver biopsy (March 2012) found lobular hepatitis 
without fibrosis (Figure 1a). The patient’s 
aminotransferases elevation (AST 4x ULN, ALT 
13,5x ULN and GGT 9x ULN) continued, motivating 
another change in the immunosuppressive therapy to 
everolimus (0.75 mg + 0.25 mg once daily). Hepatitis 
E was diagnosed on May 2012 by the presence of 
serum anti-HEV antibodies, immunoglobulin M (IgM) 
type (determined by ELISA [EUROIMMUN, Lübeck, 
Germany]), with an absence of immunoglobulin G 
(IgG). HEV RNA was detected in May 2012 in a 
serum sample by nested-PCR preceded by reverse 
transcription selective for the conserved open reading 
frame (ORF) 1 of the HEV genome [5]. The same test 
detected identical sequences in serum samples from 
July 2012 and October 2012, confirming the presence 
of chronic viremia. The amplified products obtained 
(330 bp) were sequenced and compared with 
sequences for ORF 1 HEV genotypes 1 to 4 deposited 
in GenBank through the neighbor-joining 
methodology based on the Jukes-Cantor model. 
Phylogenetic analysis demonstrated that the amplified 
product clustered with HEV genotype 3, sub-genotype 
3c (Figure 2). The doses of everolimus were reduced 
to 0.5 mg twice daily with normalization of 
aminotransferases (Figure 3). Anti-HEV IgM and IgG 
remained positive on posterior control analysis.  
 
Case 2 
The second case was a 34-year-old Caucasian male 
who received a kidney transplant from a deceased 
donor in November 2009 for CKD (probable 
hypertensive etiology). He had poorly controlled 
hypertension, medicated with nifedipine LP and 
Figure 1. Liver biopsy – a) lobular inflammatory infiltrate 
with some acidophilic bodies (H&E, 200x); b) mild peri-portal 
fibrosis; interface and lobular necroinflamatory activity (H&E, 
100× 
Figure 2. Phylogenetic analysis through MEGA5 software 
[adapted from Tamura et al., 2007]. The sequence of the 
presented case [TRSLP COIMBRA] is in bold. There were a 
total of 334 positions in the final dataset. 
Figure 3. Aminotransferase evolution and relation with 
immunosuppressive therapy. MMF: mycophenolate mofetil; 
FK: tacrolimus; Pd: prednisolone; CsA: cyclosporine; Eve: 
everolimus; MF mycophenolic acid 
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carvedilol. He denied alcohol consumption or recent 
travel abroad but was an active smoker. His BMI was 
23.2 Kg/m2. He was under immunosuppression with 
mycophenolic acid (720 mg twice daily), tacrolimus 
(12 mg once daily), and prednisolone (10 mg once 
daily). Two months after transplantation, he developed 
aminotransferase elevation, with AST 1.5x ULN, ALT 
3.5x ULN, and GGT 3x ULN. He had no symptoms. 
Serologies for HBV, HCV, HIV 1 and 2, EBV, CMV, 
and HSV were all negative. Liver autoimmunity 
screening was negative. Abdominal ultrasound was 
normal. Several changes were made in 
immunosuppressive therapy, with reduction and 
posterior conversion of tacrolimus to everolimus, and 
resulted in persistence of abnormal liver blood tests 
(Figure 3). Two years after the transplant (December 
2012), he underwent native kidney nephrectomy for 
small renal cell carcinoma, without complications. On 
January 2013, a liver biopsy was performed, revealing 
moderate chronic hepatitis with mild fibrosis (Figure 
1b). Serology for HEV (March 2013) was positive 
(IgG and IgM), and RNA HEV was detected in this 
serum sample. Unfortunately, the amplified products 
(330 bp) did not produce sequence data for 
phylogenetic analysis. Immunosuppression was 
reduced to everolimus 0.75 mg once daily and 
prednisolone 2.5 mg once daily . Because he 
maintained elevated aminotransferases, ribavirin was 
introduced at 800 mg once daily, which he will 




Hepatitis E is a frequent cause of acute hepatitis in 
developing countries and an emerging cause of 
hepatitis in industrialized countries. Typically, HEV 
causes acute, self-limited infection in 
immunocompetent patients, with a low mortality rate 
[1]. Recently, genotype 3 has been noted to be as 
responsible for hepatitis in patients submitted to solid 
organ transplant under immunosuppressive therapy, 
with about 60% of cases evolving to chronicity. 
Seroprevalence studies report the presence of the anti-
HEV IgG antibody in 6% to 16% of kidney transplant 
patients [2,6], with particular incidence in southern 
France [7]. Patients infected with hematology 
disturbances under chemotherapy and HIV-infected 
patients seem also to be at higher risk of chronic 
infection [8]. Transmission in developed countries is 
associated with the consumption of veal, pork, and 
boar meat that has been undercooked or cooked at low 
temperatures [9]. Although the mechanisms 
responsible for chronic evolution are not fully 
understood, they are at least in part connected with the 
intensity of immunosuppressive therapy [10]. The 
importance of these situations results from the 
possibility of rapid evolution to fibrosis and liver 
cirrhosis [6,11]. There is no approved treatment for 
chronic hepatitis E. In the absence of spontaneous 
resolution, reduction of immunosuppressive therapy 
should be considered, which can eliminate the virus in 
over 30% of cases [12]. Some studies point to the 
efficacy of interferon and ribavirin in the treatment of 
HEV [8,13]. In kidney transplant recipients, because 
therapy with interferon is contraindicated, three 
months of ribavirin seem effective in the elimination 
of the virus [8,12].  
Elevation of aminotransferases is, on the other 
hand, frequent in kidney transplant patients. In some 
of them, after exclusion of viral, toxic, and alcoholic 
causes, it is not possible to find any other etiology. 
Moreover, acute HEV infection can easily be confused 
with toxic hepatitis [14]. Acute presentation can, as in 
the presented cases, remain asymptomatic in over 50% 
of patients. In the remaining patients, it usually 
presents with jaundice, fatigue, weight loss, and 
diffuse myalgias or arthralgias [10]. In both of our 
patients, analytic changes began shortly after the 
transplant, with the diagnosis of hepatitis E only 
confirmed years later. Since they had no history of 
recent travel abroad, it seems likely that the infection 
had autochthonous origin. The high prevalence of 
HEV3 in domestic pigs in Portugal [15] associated 
with the high consumption of pork meat and 
derivatives in the Portuguese population leads us to 
believe that this was the source of transmission in our 
cases. Only one of the patients had histologic changes 
suggestive of chronic hepatitis, probably due to a 
longer evolution. However, evolution to chronicity is 
suggested in both cases by the changes in liver 
enzymology for more than six months, with 
persistence of RNA HEV in serum six months after 
the first detection of anti-HEV antibodies [16]. Both 
patients had anti-HEV IgM in successive 
monitorizations and were under immunosuppression 
with tacrolimus, which seems to be related with a 
higher risk of evolution to chronic hepatitis [10]. In the 
first case, the reduction of the immunosuppression 
resulted in normalization of liver enzymology, which 
was not accompanied with the correspondent anti-
HEV IgM disappearance. In the second, the 
persistence of elevated aminotransferases justified, in 
our opinion, the need to treat with ribavirin. 
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Conclusions 
To our knowledge, these are the first two cases of 
chronic hepatitis E diagnosed in Portugal. Considering 
the crescent prevalence of HEV infection, we believe 
that hepatitis E should be included in the differential 
diagnosis of elevated liver function tests, if it is not 
explained by other etiology, especially in the setting of 




Lorem ipsum dolor sit amet, consectetur adipiscing elit. 
Pellentesque at urna arcu, quis egestas dolor. Vivamus in 
diam sapien. Maecenas tempor urna vel nisi egestas 
consequat. Donec varius nisl nec leo sagittis lacinia. Proin 
elementum scelerisque nunc nec varius. 
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